Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Molecular Profiles, XenoGesis Collaborate

Published: Monday, August 04, 2014
Last Updated: Monday, August 04, 2014
Bookmark and Share
Partnership will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.

Molecular Profiles’ pharmaceutical development services will be supported by XenoGesis’ expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound’s bioavailability.

This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates, which have solubility issues during formulation development.

“We are very pleased to have struck this collaboration with the team at XenoGesis,” said Frank Condella, president and chief executive officer at Molecular Profiles’ parent company, Columbia Laboratories. ”We have complementary service offerings which allow us to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to our enabling technologies package.

“For us, this will build-upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies,” concluded Mr. Condella.

XenoGesis was founded by its managing director, Richard Weaver Ph.D., after a 15-year career at AstraZeneca. The company specializes in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body.

Dr. Weaver commented, “Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients.  We will be able to give them a better understanding of their compounds during pre-clinical work, which in turn, will reduce cost and provide a quicker route to market.”

Working with leading drug development companies across the world, Columbia Laboratories’ Molecular Profiles subsidiary specializes in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support.

The company recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology at its clinical manufacturing facility to further enhance its expertise in the processing of difficult-to-progress molecules.

Alongside its development capabilities, its MHRA-licensed site enables the company to manufacture a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds and controlled drugs.



Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!